Literature DB >> 2504123

Endocarditis due to streptomycin-susceptible Enterococcus faecalis with high-level gentamicin resistance.

C A Spiegel1, M Huycke.   

Abstract

A case of community-acquired endocarditis caused by Enterococcus (Streptococcus) faecalis with high-level resistance to gentamicin sulfate but not to streptomycin sulfate is described. Killing curves performed using achievable serum levels showed synergistic killing when streptomycin but not gentamicin, tobramycin, or amikacin was combined with penicillin G sodium or vancomycin hydrochloride. Combination therapy with vancomycin and streptomycin resulted in cure. Serum bactericidal levels indicated activity of the synergistic, as well as a nonsynergistic (vancomycin plus gentamicin), combination. Routine screening of blood isolates for high-level resistance to streptomycin and gentamicin can provide guidance for selection of therapeutic combinations in serious enterococcal infections, including endocarditis.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2504123

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  8 in total

1.  Increasing Antimicrobial Resistance: Therapeutic Implications for Enterococcal Infections.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-10       Impact factor: 3.725

Review 2.  Screening and treatment of infections caused by resistant enterococci.

Authors:  D J Herman; D N Gerding
Journal:  Antimicrob Agents Chemother       Date:  1991-02       Impact factor: 5.191

Review 3.  Antimicrobial resistance among enterococci.

Authors:  D J Herman; D N Gerding
Journal:  Antimicrob Agents Chemother       Date:  1991-01       Impact factor: 5.191

4.  Factors influencing determination of high-level aminoglycoside resistance in Enterococcus faecalis.

Authors:  D F Sahm; S Boonlayangoor; P C Iwen; J L Baade; G L Woods
Journal:  J Clin Microbiol       Date:  1991-09       Impact factor: 5.948

5.  Efficacy of vancomycin and teicoplanin alone and in combination with streptomycin in experimental, low-level vancomycin-resistant, VanB-type Enterococcus faecalis endocarditis.

Authors:  D P Nicolau; M N Marangos; C H Nightingale; K B Patel; B W Cooper; R Quintiliani; P Courvalin; R Quintiliani
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

6.  Bacteremia caused by hemolytic, high-level gentamicin-resistant Enterococcus faecalis.

Authors:  M M Huycke; C A Spiegel; M S Gilmore
Journal:  Antimicrob Agents Chemother       Date:  1991-08       Impact factor: 5.191

7.  Bactericidal activity of the fluoroquinolone WIN 57273 against high-level gentamicin-resistant Enterococcus faecalis.

Authors:  G A Noskin; P Mehl; J R Warren
Journal:  Antimicrob Agents Chemother       Date:  1993-11       Impact factor: 5.191

8.  Continuous intravenous versus intermittent ampicillin therapy of experimental endocarditis caused by aminoglycoside-resistant enterococci.

Authors:  W C Hellinger; M S Rouse; P M Rabadan; N K Henry; J M Steckelberg; W R Wilson
Journal:  Antimicrob Agents Chemother       Date:  1992-06       Impact factor: 5.191

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.